SG Americas Securities LLC Has $147,000 Position in Cullinan Oncology, Inc. (NASDAQ:CGEM)

SG Americas Securities LLC boosted its holdings in Cullinan Oncology, Inc. (NASDAQ:CGEM) by 12.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,449 shares of the company’s stock after purchasing an additional 1,587 shares during the quarter. SG Americas Securities LLC’s holdings in Cullinan Oncology were worth $147,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Nuveen Asset Management LLC lifted its stake in Cullinan Oncology by 1.3% during the 3rd quarter. Nuveen Asset Management LLC now owns 107,360 shares of the company’s stock valued at $1,376,000 after acquiring an additional 1,347 shares in the last quarter. Rhumbline Advisers lifted its stake in Cullinan Oncology by 4.7% during the 1st quarter. Rhumbline Advisers now owns 32,045 shares of the company’s stock valued at $336,000 after acquiring an additional 1,445 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Cullinan Oncology by 5.6% during the 4th quarter. Alliancebernstein L.P. now owns 28,200 shares of the company’s stock valued at $298,000 after acquiring an additional 1,500 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Cullinan Oncology by 7.9% during the 2nd quarter. California State Teachers Retirement System now owns 23,485 shares of the company’s stock worth $253,000 after purchasing an additional 1,719 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Cullinan Oncology by 15.9% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 13,617 shares of the company’s stock worth $175,000 after purchasing an additional 1,871 shares during the period. 86.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CGEM shares. Wedbush started coverage on Cullinan Oncology in a research note on Thursday, February 15th. They set an “outperform” rating and a $30.00 target price on the stock. William Blair assumed coverage on Cullinan Oncology in a research note on Monday. They issued an “outperform” rating on the stock. Finally, HC Wainwright lowered their price objective on Cullinan Oncology from $34.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cullinan Oncology presently has a consensus rating of “Buy” and an average target price of $27.00.

Cullinan Oncology Stock Up 4.7 %

CGEM stock opened at $17.32 on Wednesday. The firm has a market capitalization of $745.97 million, a PE ratio of -4.69 and a beta of 0.33. Cullinan Oncology, Inc. has a twelve month low of $7.64 and a twelve month high of $20.62. The stock has a 50-day simple moving average of $17.30 and a two-hundred day simple moving average of $12.53.

Cullinan Oncology (NASDAQ:CGEM) last posted its earnings results on Thursday, March 14th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.42. On average, equities research analysts anticipate that Cullinan Oncology, Inc. will post -3.55 EPS for the current fiscal year.

Insider Transactions at Cullinan Oncology

In other news, insider Corrine Savill sold 40,000 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $14.09, for a total transaction of $563,600.00. Following the completion of the transaction, the insider now owns 165,990 shares of the company’s stock, valued at $2,338,799.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 98,684 shares of company stock valued at $1,437,624. 8.82% of the stock is owned by corporate insiders.

Cullinan Oncology Company Profile

Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.